Fredrik Celsing

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Jeanette Lundin, Eva Kimby, Magnus Björkholm et al. · Blood · 2002 · 496 citations · Full text

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

Gunnar Juliusson, Fredrik Celsing, Ingemar Turesson et al. · British Journal of Haematology · 2000 · 245 citations · Full text

Hematological Malignancy, Best Response, Health Sciences +15

Changes in plasma concentrations of aromatic and branched‐chain amino acids during sustained exercise in man and their possible role in fatigue

Eva Blomstrand, Fredrik Celsing, Eric A. Newsholme · Acta Physiologica Scandinavica · 1988 · 233 citations

Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden

Anders Österborg, Magnus Björkholm, Mats Björeman et al. · Blood · 1993 · 105 citations · Full text

Effects of iron deficiency on endurance and muscle enzyme activity in man

Fredrik Celsing, Eva Blomstrand, BJ RN WERNER et al. · Medicine & Science in Sports & Exercise · 1986 · 104 citations

Nutrition, Iron Metabolism, Repeated Venesections +17